Solid Biosciences Inc.
Close on Oct 19, 2026
- Market cap
- $850.64M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 6, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 18, 2025 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 9, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | Before market open | $6.20M | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | Apr 27, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Jan 10, 2022 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 16, 2021 | After market close | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 14, 2021 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 15, 2021 | After market close | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Oct 23, 2020 | Before market open | – | – | – |
Press releases
Announcements Solid Biosciences filed with the SEC
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
[Graphic Appears Here] November 2 0 2 5 Corporate Presentation 87050-004-Part-503Nov25 13:39Page 22[Graphic Appears Here]
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Solid Biosciences Announces Pricing of Underwritten Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Cautionary Note Regarding Forward Looking Statements This presentation
Results of operations · Other events · EX-99.1 to Form 8-K
42nd Annual J.P. Morgan Healthcare
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Solid Biosciences Announces $109 Million Private Placement
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference JANUARY 12, 2023 Exhibit 99.1
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
Material agreement · Acquisition or disposition completed · Exit or restructuring costs · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
To the Stockholders and the Board of Directors of AavantiBio, Inc.
Material agreement · Acquisition or disposition completed · Exit or restructuring costs · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
INDEX TO CONDENSED FINANCIAL STATEMENTS
Material agreement · Acquisition or disposition completed · Exit or restructuring costs · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
Executive or director change · Shareholder vote results · Other events · EX-99.2 to Form 8-K
Caitlin Lowie - VP, Communications and IR, Solid Biosciences
Regulation FD disclosure · EX-99.1 to Form 8-K
On September 30, 2022, Solid Biosciences Inc. published the following post on LinkedIn:
Regulation FD disclosure · EX-99.2 to Form 8-K
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
September 30, 2022 © 2022 Solid Biosciences 1
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
Results of operations · EX-99.1 to Form 8-K
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
Results of operations · Other events · EX-99.1 to Form 8-K